Prevention of Respiratory Viruses using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)
Undergoing allogeneic hematopoietic transplant for malignant or non-malignant disease
Capable of providing informed consent
Planned to receive follow-up at the transplant site for the first 100 days post transplantation
Subjects who the investigator believes can and will comply with the study protocol
Other eligibility criteria may apply.
Documented respiratory viral infection in the two weeks prior to enrollment
Current or planned use of any prophylactic antiviral therapy, antibody treatments, or other agents targeting the prevention of respiratory viruses (i.e. oseltamivir, ribavirin, amantadine)
Known allergy to study drug components (jojoba, orange oil, coconut oil, lauric acid, benzalkonium chloride, vitamin E)
Receiving oxygen supplementation at time of enrollment
Active mucositis at time of enrollment
Ongoing irritation or active infection of the squamous epithelial cell skin involving the nose or nasal vestibule
Daily use of nasal decontamination products or other nasal medications (e.g. nasal steroids)
Unable to complete study procedures (e.g. nasal swab self-testing)
Other exclusion criteria may apply.